• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Dr. Lerner on the pivotal OLYMPUS trial of Jelmyto in UTUC

Video

“Of the 42 patients who achieved a complete response, 41 of those were evaluable for duration of response, which was the focus of the manuscript that was just published last month,” says Seth P. Lerner, MD.

In this video, Seth P. Lerner, MD, discusses the background of the OLYMPUS trial, which has now released its final report. The phase 3 trial supported the FDA approval of mitomycin-containing reverse thermal gel (UGN-101; Jelmyto) for the treatment of patients with low-grade upper tract urothelial cancer.

Lerner is a professor in the Scott Department of Urology and Beth and Dave Swalm Chair in urologic oncology at the Baylor College of Medicine Medical Center in Houston, Texas.

Related Videos
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
doctor showing a patient some information on a digital tablet | Image Credit: © bongkarn - stock.adobe.com
Blurred interior of hospital | Image Credit: © jakkapan - stock.adobe.com
A panel of 5 experts on bladder cancer
A panel of 5 experts on bladder cancer
Diverse doctors having a conversation |  Image Credit: © Flamingo Images - stock.adobe.com
David I. Lee, MD, FACS, answers a question during a video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.